EN
HI

SHILPA MEDICARE Share price

SHILPAMED

HealthcareMid

635.45

33.45 (-5.00%)
NSE
BSE
Last updated on 6 May, 2025 | 15:56 IST
BUYSELL
Today's High

633.00

Today's Low

672.60

52 Week Low

959.50

52 Week High

959.50

The current prices are delayed, login to your account for live prices

Shilpa Medicare Chart

SHILPA MEDICARE Share Key Metrics

Volume
1.92 L
Market Cap
6214.12 CR
LTQ@LTP
1@635.45
ATP
650.87
Var Margin
2380
Circuit Range
535.15-802.65
Delivery %
41.96
Value
12.47 CR
ASM/GSM
No
Market Lot
1

SHILPA MEDICARE Futures & Options

Data Not Found

SHILPA MEDICARE Corporate Actions

DateAgenda
2025-02-10Quarterly Results
DateEvent TypeAgenda
2025-02-10Board MeetingQuarterly Results

SHILPA MEDICARE News

Shilpa Medicare shares rise 6% on CEP approvals from EDQM

Nov 19 2024 13:36:51

AstraZeneca Pharma, Themis Medicare, PG Electroplast, Shilpa Medicare in Focus | Stocks On Radar

Nov 19 2024 11:51:51

Shilpa Medicare share jumps 8% as Q2 earnings impress

Nov 14 2024 11:36:55

Shilpa Medicare share jumps 8% as Q2 earnings impress

Nov 14 2024 11:31:54
Read More

About SHILPA MEDICARE

NSE : 17752  
BSE : 530549  
ISIN : INE790G01031  

Shilpa Antibiotics Ltd was incorporated as a PrivateLimited Company in November 1987. The commercialproduction of the Company had started in November 1989.The Company was initially producing Trimethoprim IP/BP anantibiotic bulk drug. The technology for the bulk drug wasdeveloped in house. During the first year of its operationthe Company had installed production facilities tomanufacture Trimethoprim Apart from selling on its own theCompany had also started manufacturing the product forother reputed Companies like Eskayef Limited Bombay Drugsand Pharmas Limited Bombay Drug House Ltd. US VitaminsLtd Sandoz India Ltd etc for their export commitments.During 1992 the Company had installed productionfacilities for manufacture of Sodium Methoxide. Thetechnology for the same had also been developed in house.During the same year the Company secured Export orders fromStellar Exports Limited Glaxo Limited and Deepak NitriteLimited for Trimethoprim. Since then the company hasstarted exporting on its own. The Company thus startedmanufacturing for both export and domestic markets since1992. It has obtained World Health Organisation-GoodManufacturing Practices (GMP) Certificate. It has alsobeen exporting its products to hard currency areas.The Company now proposes to embark upon an expansionproject which involves the addition of one more bulk drugto its existing product range viz; Norfloxcin and expansionof the production capacity of the existing product of theCompany viz; Sodium Methoxide and Trimethoprim. TheCompany also proposes to manufacture 1-MethylAmino-1-Methyl Thio-2-Nitro Ethane a drug intermediateused in the manufacture of Ranitidine an anti-ulcer drug.To raise the necessary resources to finance the expansionproject of the Company the Company was converted into aPublic Limited Company in November 1993.As the company''s sales are comparatively more in theSeptember to March period therefore to reduce theadministrative bottlenecks in the timely preparation ofannual results the company changed its accounting yearfrom March end to September end.Objects of the CompanyThe relevant objects of the company as set out in thememorandum of association of the company are :Main Objects1. To carry on in India or elsewhere the industry trade orbusiness of manufacturers Traders Dealers AgentsSuppliers Licensors Licensees Loan Licenses ImportersExporters Consultants Discoverers Inventors andProducers of Drugs Bulk Drugs PharmaceuticalsPharmaceutical Formulations Alcohol Bended LaboratoryPreparations and general medicinal preparation and ortheir by-products and packing and re-packing of the above.

SHILPA MEDICARE Management

NamePosition
Mr. Omprakash Inani Chairman
Mr. Vishnukant C Bhutada Managing Director
Mr. Kalakota Sharath Reddy Whole Time Director
Mr. Hetal Madhukant Gandhi Independent Director
Mr. Arvind Vasudeva Independent Director
Read More

SHILPA MEDICARE FAQs

The Buying Price of SHILPA MEDICARE share is 275.7 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy SHILPA MEDICARE share to your Choice trading account, or open a Choice Demat account, then add funds, search the company name, select your order type, and place your trade.

The Price-to-earnings (P/E) ratio of SHILPA MEDICARE shares is 77.1. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio SHILPA MEDICARE shares is 2.41. Useful to assess the stock's value relative to its book value.

To assess SHILPA MEDICARE’s valuation compare Sector P/E, P/B which are 34.16 & 4.86 with sector averages, along with growth rates and financial metrics.

The Market Cap of SHILPA MEDICARE is 6214.12 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of SHILPA MEDICARE share price is 959.50 & 417.60. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.